GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Quick Ratio

ANTH (Anthera Pharmaceuticals) Quick Ratio : 3.30 (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Anthera Pharmaceuticals's quick ratio for the quarter that ended in Mar. 2018 was 3.30.

Anthera Pharmaceuticals has a quick ratio of 3.30. It generally indicates good short-term financial strength.

The historical rank and industry rank for Anthera Pharmaceuticals's Quick Ratio or its related term are showing as below:

ANTH's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful Quick Ratio only.

Anthera Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Anthera Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Quick Ratio Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 0.53 5.65 2.14 0.68

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 3.28 1.97 0.68 3.30

Competitive Comparison of Anthera Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Anthera Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Quick Ratio falls into.


;
;

Anthera Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Anthera Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Quick Ratio (A: Dec. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(3.191-0)/4.711
=0.68

Anthera Pharmaceuticals's Quick Ratio for the quarter that ended in Mar. 2018 is calculated as

Quick Ratio (Q: Mar. 2018 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(8.739-0)/2.646
=3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals  (OTCPK:ANTH) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Anthera Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022